<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83746">
  <stage>Registered</stage>
  <submitdate>21/03/2009</submitdate>
  <approvaldate>15/05/2009</approvaldate>
  <actrnumber>ACTRN12609000276257</actrnumber>
  <trial_identification>
    <studytitle>Efficacy and safety of artemeter-lumefantrine in the treatment of uncomplicated malaria-causing Plasmodium falciparum infections in Botswana</studytitle>
    <scientifictitle>Efficacy and safety of artemeter-lumefantrine in the treatment of uncomplicated malaria-causing Plasmodium falciparum infections in Botswana</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Antimalarial medicine efficacy</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>artemether-lumefantrine, 20 mg artemether and 120 mg lumefantrine per tablet, malaria treatment, oral treatment 1 tablet for 5-14 kg, 2 tablets for 15-24 kg, 3 tablets 25-34, 4 tablets over 35 kg twice a day over 3 days</interventions>
    <comparator>No control</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical efficacy monitored by health care professionals by clinical eximaniation and temperature measurement and parasitological efficacy monitored by labortaory techniciansby thick blood smear</outcome>
      <timepoint>28 days post-testing initial treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Prevalence of side effects assessed by questionnaire</outcome>
      <timepoint>28 days post-testing initial treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>age six months and above; 
mono-infection with Plasmodium falciparum detected by microscopy;
parasitaemia of 500200 000 asexual forms /microl blood;
presence of axillary temperature = 37.5 degre C and/or history of fever during the past 24 h;
ability to swallow oral medication;
ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
informed consent from the patient or from a parent or guardian in the case of children.</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Months</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of World Health Organization;
mixed or mono-infection with another Plasmodium species detected by microscopy;
presence of severe malnutrition (defined as a child whose growth standard is below 3 Z score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference &lt; 110 mm);
presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, human immunodeficiency virus/acquired immunodeficiency syndrome);
regular medication, which may interfere with antimalarial pharmacokinetics;
history of hypersensitivity reactions or contraindications to any of the drug(s) being tested or used as alternative treatment(s); and
a positive pregnancy test or breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>261</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Botswana</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Ministry of Health</primarysponsorname>
    <primarysponsoraddress>P/bag 00269 Gaborone</primarysponsoraddress>
    <primarysponsorcountry>Botswana</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Ministry of Health</fundingname>
      <fundingaddress>P/bag 00269 Gaborone</fundingaddress>
      <fundingcountry>Botswana</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To assess the efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated P. falciparum infections among people older than 6 months in Chobe, Okavango and Tutume districts in Botswana.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ministry of Health</ethicname>
      <ethicaddress>P/bag 00269 Gaborone</ethicaddress>
      <ethicapprovaldate>17/02/2009</ethicapprovaldate>
      <hrec>PPME/13/18/1</hrec>
      <ethicsubmitdate />
      <ethiccountry>Botswana</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Ringwald Pascal</name>
      <address>20 avenue Appia
1211 Geneva 27</address>
      <phone>+ 41 22 791 34 69</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ringwald Pascal</name>
      <address>20 avenue Appia
1211 Geneva 27</address>
      <phone>+ 41 22 791 34 69</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Ringwald Pascal</name>
      <address>20 avenue Appia
1211 Geneva 27</address>
      <phone>+ 41 22 791 34 69</phone>
      <fax />
      <email>ringwaldp@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>